NASDAQ:VRDN Viridian Therapeutics (VRDN) Stock Price, News & Analysis → Do This Today BEFORE Biden Wins in November (From Stansberry Research) (Ad) Free VRDN Stock Alerts $13.90 -0.01 (-0.07%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$13.34▼$14.0550-Day Range$12.70▼$19.8952-Week Range$10.93▼$28.35Volume858,045 shsAverage Volume797,704 shsMarket Capitalization$887.10 millionP/E RatioN/ADividend YieldN/APrice Target$34.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Viridian Therapeutics alerts: Email Address Viridian Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.82 Rating ScoreUpside/Downside148.9% Upside$34.60 Price TargetShort InterestBearish14.59% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.15Based on 32 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.39) to ($4.29) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.87 out of 5 starsMedical Sector609th out of 921 stocksMedical Laboratories Industry15th out of 20 stocks 4.4 Analyst's Opinion Consensus RatingViridian Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 9 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageViridian Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Viridian Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted14.59% of the outstanding shares of Viridian Therapeutics have been sold short.Short Interest Ratio / Days to CoverViridian Therapeutics has a short interest ratio ("days to cover") of 10.2, which indicates bearish sentiment.Change versus previous monthShort interest in Viridian Therapeutics has recently decreased by 4.32%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldViridian Therapeutics does not currently pay a dividend.Dividend GrowthViridian Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VRDN. Previous Next 1.7 News and Social Media Coverage News SentimentViridian Therapeutics has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 32 news articles for Viridian Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 11 people have searched for VRDN on MarketBeat in the last 30 days. This is a decrease of -8% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Viridian Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -13% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Viridian Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.43% of the stock of Viridian Therapeutics is held by insiders.Read more about Viridian Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Viridian Therapeutics are expected to grow in the coming year, from ($4.39) to ($4.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Viridian Therapeutics is -2.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Viridian Therapeutics is -2.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioViridian Therapeutics has a P/B Ratio of 3.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Viridian Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchDo This Today BEFORE Biden Wins in NovemberDiscover "U.S.'s New Money" Before Biden Wins A new form of money has emerged in America, and it's making some folks wildly rich… (Musk and Bezos both use it).Find out how you can too in this free video. About Viridian Therapeutics Stock (NASDAQ:VRDN)Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.Read More VRDN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VRDN Stock News HeadlinesMay 10, 2024 | markets.businessinsider.comAnalyst Issues Buy Rating for Viridian Therapeutics Amid Positive Clinical Progress and Strategic BLA Submission PlanMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Viridian Therapeutics Amidst Accelerated Clinical Progress and Market Expansion PotentialMay 10, 2024 | Stansberry Research (Ad)Do This Today BEFORE Biden Wins in NovemberDiscover "U.S.'s New Money" Before Biden Wins A new form of money has emerged in America, and it's making some folks wildly rich… (Musk and Bezos both use it).May 10, 2024 | businesswire.comViridian Therapeutics to Participate in Upcoming May Investor ConferencesMay 10, 2024 | msn.comLadenburg Thalmann Downgrades Viridian Therapeutics (VRDN)May 10, 2024 | americanbankingnews.comViridian Therapeutics (NASDAQ:VRDN) Shares Gap Down Following Analyst DowngradeMay 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Viridian Therapeutics on Strong Clinical Trials and Promising Drug ProspectsMay 9, 2024 | msn.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Q1 2024 Earnings Call TranscriptMay 10, 2024 | Stansberry Research (Ad)Do This Today BEFORE Biden Wins in NovemberDiscover "U.S.'s New Money" Before Biden Wins A new form of money has emerged in America, and it's making some folks wildly rich… (Musk and Bezos both use it).May 9, 2024 | finance.yahoo.comViridian Therapeutics Inc (VRDN) Q1 2024 Earnings Call Transcript Highlights: Strategic ...May 9, 2024 | finance.yahoo.comViridian Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagMay 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Viridian Therapeutics Amidst Strong Pipeline Progress and Solid Financial StandingMay 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Viridian Therapeutics on Promising VRDN-001 Trials and Strong Financial OutlookMay 8, 2024 | finance.yahoo.comViridian Therapeutics Inc (VRDN) Q1 2024 Earnings: Narrowing Losses Amidst Clinical AdvancementsMay 8, 2024 | investorplace.comVRDN Stock Earnings: Viridian Therapeutics Beats EPS, Beats Revenue for Q1 2024May 8, 2024 | seekingalpha.comViridian Therapeutics, Inc. 2024 Q1 - Results - Earnings Call PresentationMay 8, 2024 | businesswire.comViridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial ResultsMay 7, 2024 | globenewswire.comPacific Urban Investors Expands Denver Portfolio with Acquisition of Viridian Apartment Community in Greenwood VillageMay 3, 2024 | businesswire.comViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 29, 2024 | businesswire.comViridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024April 13, 2024 | fool.comViridian Therapeutics (NASDAQ: VRDN)April 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for Viridian Therapeutics Amidst TED Treatment Market PotentialApril 4, 2024 | businesswire.comViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 29, 2024 | prnewswire.comVIRIDIAN SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the FirmMarch 25, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), OmniAb (OABI) and Vericel (VCEL)March 20, 2024 | markets.businessinsider.comBuy Rating Endorsed for Viridian Therapeutics’ VRDN Treatments Based on Superior Efficacy and Dosing Advantages in TED MarketMarch 20, 2024 | markets.businessinsider.comUnveiling 4 Analyst Insights On Viridian TherapeuticsSee More Headlines Receive VRDN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Viridian Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today5/10/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:VRDN CUSIPN/A CIK1590750 Webwww.viridiantherapeutics.com Phone(617) 272-4600Fax760-537-4101Employees94Year FoundedN/APrice Target and Rating Average Stock Price Target$34.60 High Stock Price Target$46.00 Low Stock Price Target$20.00 Potential Upside/Downside+157.1%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($5.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-237,730,000.00 Net Margins-75,711.48% Pretax Margin-75,711.46% Return on Equity-121.80% Return on Assets-61.06% Debt Debt-to-Equity Ratio0.09 Current Ratio18.26 Quick Ratio18.26 Sales & Book Value Annual Sales$310,000.00 Price / Sales2,771.02 Cash FlowN/A Price / Cash FlowN/A Book Value$4.48 per share Price / Book3.00Miscellaneous Outstanding Shares63,820,000Free Float62,909,000Market Cap$859.02 million OptionableOptionable Beta1.14 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Stephen F. Mahoney J.D. (Age 53)MBA, CEO, President & Director Dr. Eric N. Olson Ph.D.Co-Founder & Chairman of Scientific Advisory BoardDr. Michael R. Bristow M.D. (Age 79)Ph.D., Co-Founder & Member of the Scientific Advisory Board Dr. Marvin H. Caruthers Ph.D. (Age 84)Co-Founder & Scientific Advisory Board Member Mr. Vahe Bedian Ph.D.Co-Founder & Scientific AdvisorMr. Seth HarmonSenior VP of Finance and Accounting, Principal Financial & Accounting OfficerMr. Thomas W. Beetham J.D. (Age 54)MBA, Chief Operating Officer Ms. Jennifer Tousignant J.D.Chief Legal OfficerMr. John A. JordanVice President of Investor Relations & Corporate CommunicationsMr. Anthony Casciano (Age 47)Chief Commercial Officer More ExecutivesKey CompetitorsCastle BiosciencesNASDAQ:CSTLFulgent GeneticsNASDAQ:FLGTCareDxNASDAQ:CDNACelcuityNASDAQ:CELCVeracyteNASDAQ:VCYTView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 233,331 shares on 5/10/2024Ownership: 5.068%State Board of Administration of Florida Retirement SystemSold 2,500 shares on 5/9/2024Ownership: 0.015%Russell Investments Group Ltd.Sold 7,878 shares on 5/8/2024Ownership: 0.504%Swiss National BankBought 15,700 shares on 5/7/2024Ownership: 0.130%Mirae Asset Global Investments Co. Ltd.Bought 1,135 shares on 5/1/2024Ownership: 0.045%View All Insider TransactionsView All Institutional Transactions VRDN Stock Analysis - Frequently Asked Questions Should I buy or sell Viridian Therapeutics stock right now? 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Viridian Therapeutics in the last twelve months. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" VRDN shares. View VRDN analyst ratings or view top-rated stocks. What is Viridian Therapeutics' stock price target for 2024? 11 equities research analysts have issued 12-month price targets for Viridian Therapeutics' stock. Their VRDN share price targets range from $20.00 to $46.00. On average, they expect the company's share price to reach $34.60 in the next year. This suggests a possible upside of 148.9% from the stock's current price. View analysts price targets for VRDN or view top-rated stocks among Wall Street analysts. How have VRDN shares performed in 2024? Viridian Therapeutics' stock was trading at $21.78 at the start of the year. Since then, VRDN shares have decreased by 36.2% and is now trading at $13.90. View the best growth stocks for 2024 here. When is Viridian Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our VRDN earnings forecast. How were Viridian Therapeutics' earnings last quarter? Viridian Therapeutics, Inc. (NASDAQ:VRDN) released its quarterly earnings data on Wednesday, May, 8th. The company reported ($0.79) earnings per share for the quarter, topping the consensus estimate of ($1.07) by $0.28. The business earned $0.07 million during the quarter, compared to analyst estimates of $0.09 million. Viridian Therapeutics had a negative net margin of 75,711.48% and a negative trailing twelve-month return on equity of 121.80%. Viridian Therapeutics's quarterly revenue was down 26.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.61) earnings per share. Who are Viridian Therapeutics' major shareholders? Viridian Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (5.07%), Russell Investments Group Ltd. (0.50%), Rosalind Advisors Inc. (0.48%), Hennion & Walsh Asset Management Inc. (0.17%), Swiss National Bank (0.13%) and Mirae Asset Global Investments Co. Ltd. (0.05%). Insiders that own company stock include Barrett Katz, Fairmount Funds Management Llc, Jonathan Violin, Lara Meisner, Life Sciences Public F Frazier and Scott Dunseth Myers. View institutional ownership trends. How do I buy shares of Viridian Therapeutics? Shares of VRDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VRDN) was last updated on 5/10/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaGold Set to EXPLODE!Gold Safe ExchangeHe Is Giving Away BitcoinCrypto Swap ProfitsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingMissed NVDA? Buy this AI stock NOWChaikin AnalyticsCharles Payne Demystifies OptionsUnstoppable ProsperityYou need to know these two things about AI stocks ASAP…InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viridian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
